SER

Company Overview — What Does Serina Therapeutics, Inc. Do?

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama. Serina Therapeutics, Inc. (SER) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Steven A. Ledger. With a market capitalization of $26M, SER is one of the notable companies in the Healthcare sector.

Serina Therapeutics, Inc. (SER) Stock Rating — Avoid (April 2026)

As of April 2026, Serina Therapeutics, Inc. receives a Avoid rating with a composite score of 21.4/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.SER ranks #4,295 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Serina Therapeutics, Inc. ranks #782 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

SER Stock Price and 52-Week Range

Serina Therapeutics, Inc. (SER) currently trades at $1.92. The stock lost $0.08 (4.0%) in the most recent trading session. The 52-week high for SER is $7.92, which means the stock is currently trading -75.8% from its annual peak. The 52-week low is $1.22, putting the stock 57.4% above its annual trough. Recent trading volume was 0 shares, suggesting relatively thin trading activity.

Is SER Overvalued or Undervalued? — Valuation Analysis

Serina Therapeutics, Inc. (SER) carries a value factor score of 11/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 17.19x, versus the sector average of 2.75x. The price-to-sales ratio is 177.87x, compared to 1.66x for the average Healthcare stock.

At current multiples, Serina Therapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Serina Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

Serina Therapeutics, Inc. (SER) earns a quality factor score of 10/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -909.4%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -208.6% versus the sector average of -33.1%.

The operating margin is -21111.8% (sector: -66.1%). Net profit margin stands at 2453.9%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -100.0% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

SER Debt, Balance Sheet, and Financial Health

Serina Therapeutics, Inc. has a debt-to-equity ratio of 679.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 1.71x, suggesting adequate working capital coverage. Total debt on the balance sheet is $3M. Cash and equivalents stand at $9M.

SER has a beta of 0.55, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Serina Therapeutics, Inc. is 28/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Serina Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Serina Therapeutics, Inc. reported revenue of $144,000 and earnings per share (EPS) of $-1.91. Net income for the quarter was $-14M. Operating income came in at $-23M.

In FY 2025, Serina Therapeutics, Inc. reported revenue of $130,000 and earnings per share (EPS) of $-1.91. Net income for the quarter was $-19M. Revenue grew 132.1% year-over-year compared to FY 2024. Operating income came in at $-24M.

In Q3 2025, Serina Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.45. Net income for the quarter was $-5M. Operating income came in at $-6M.

In Q2 2025, Serina Therapeutics, Inc. reported revenue of $130,000 and earnings per share (EPS) of $-0.66. Net income for the quarter was $-6M. Revenue grew 154.9% year-over-year compared to Q2 2024. Operating income came in at $-6M.

Over the past 8 quarters, Serina Therapeutics, Inc. has demonstrated a growth trajectory, with revenue expanding from $51,000 to $144,000. Investors analyzing SER stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

SER Dividend Yield and Income Analysis

Serina Therapeutics, Inc. (SER) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

SER Momentum and Technical Analysis Profile

Serina Therapeutics, Inc. (SER) has a momentum factor score of 14/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 40/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 67/100 reflects moderate short selling activity.

SER vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Serina Therapeutics, Inc. (SER) ranks #782 out of 838 stocks based on the Blank Capital composite score. This places SER in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing SER against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full SER vs S&P 500 (SPY) comparison to assess how Serina Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

SER Next Earnings Date

No upcoming earnings date has been announced for Serina Therapeutics, Inc. (SER) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy SER? — Investment Thesis Summary

The quantitative profile for Serina Therapeutics, Inc. suggests caution. The quality score of 10/100 flags below-average profitability. The value score of 11/100 indicates premium valuation. Momentum is weak at 14/100, a headwind for near-term performance. High volatility (stability score 28/100) increases portfolio risk.

In summary, Serina Therapeutics, Inc. (SER) earns a Avoid rating with a composite score of 21.4/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on SER stock.

Related Resources for SER Investors

Explore more research and tools: SER vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare SER head-to-head with peers: SER vs AZN, SER vs SLGL, SER vs VMD.